By
German medical technology leader Ottobock SE & Co. KGaA has reported record financial results for the 2025 fiscal year, reflecting strong global demand, product innovation, and successful strategic initiatives. Preliminary figures indicate that the company’s core revenue rose by 11.7 % to about €1.6 billion, marking a significant increase compared with the previous year. Underlying profitability also improved sharply, with core EBITDA climbing nearly 30 % to roughly €415 million and a corresponding EBITDA margin of around 26 %.
This performance underscores Ottobock’s continued leadership in orthopaedics, prosthetics, and broader human bionics markets. According to the company, successful new product introductions — including advanced knee joints and redesigned arm and hand prosthetic lines — helped fuel sales growth, alongside strategic acquisitions that have strengthened its Patient Care network in key markets such as Belgium and Australia. Across regions, core revenue grew by double digits in EMEA, while the Americas and APAC also delivered strong contributions.
In addition to expanded revenue and profit margins, Ottobock’s financial position improved through enhanced free cash flow and reductions in net debt, further bolstering its balance sheet. The company has also reaffirmed its positive growth outlook for 2026, projecting core business growth of between 5 % and 8 % and continued margin expansion. Over the medium term — through to 2029 — Ottobock expects ongoing organic growth of 7 % to 9 % as it continues to invest in innovation and global market expansion.
Ottobock’s results reflect a broader trend of sustained demand for advanced prosthetic and orthotic technologies, as well as the effectiveness of its long-term strategy combining innovation, targeted acquisitions, and operational efficiency.
